Efficacy and Safety of Diclofenac Sodium Gel in Knee Osteoarthritis
Launched by NOVARTIS · Sep 13, 2005
Trial Information
Current as of May 24, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- • Key Inclusion criteria
- • Osteoarthritis of the knee Key Exclusion criteria
- • Other rheumatic disease, such as rheumatoid arthritis
- • Active gastrointestinal ulcer during the last year
- • Known allergy to analgesic drugs
About Novartis
Novartis is a global healthcare company based in Switzerland, dedicated to reimagining medicine to improve and extend people's lives. With a strong focus on innovative pharmaceuticals, Novartis engages in the research, development, and commercialization of a wide range of therapies across various therapeutic areas, including oncology, cardiology, immunology, and neuroscience. The company is committed to advancing clinical research through rigorous trials that prioritize patient safety and efficacy, aiming to deliver groundbreaking treatments and solutions that address unmet medical needs worldwide. Novartis's commitment to innovation and collaboration positions it at the forefront of the biopharmaceutical industry, driving advancements that enhance patient care and health outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Parsippany, New Jersey, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials